# US 2026/0085285 A1 · Methods for producing retinal pigment epithelium cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085285 A1
- Document ID: US20260085285A1
- Status: Published application
- Kind: A1
- Application number: 19/408,516
- Filed: 2025-12-04
- Published: 2026-03-26
- Earliest claimed: 2018-06-20
- Assignees: Biolamina AB
- Applicants: BioLamina AB
- Inventors: Karl Anders Fredrik Lanner; Álvaro Plaza Reyes; Sandra Petrus Reurer; Sara Padrell Sánchez
- Web page: https://patentgrep.com/patent/US20260085285A1

## CPC

- C12N 5/062: {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
- C12N 5/0621: {Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062)}
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61P 27/02: Ophthalmic agents
- C12N 2500/98: Xeno-free medium and culture conditions
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/02: from embryonic cells
- C12N 2533/52: Fibronectin; Laminin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods comprise exposing a culture of human pluripotent stem cells adherent on a first substrate comprising a first laminin to a differentiation medium for a first time period of 15 days to 50 days to obtain a first population of adherent cells comprising RPE cells and/or progenitors thereof; at the end of the first time period, dissociating the first population from the first substrate; replating the dissociated first population of cells on a second substrate comprising a second laminin; and culturing the replated first population of cells on the second substrate for a second time period to obtain an expanded and matured second population of cells comprising the RPE cells. The first and second laminins are independently selected from LN-521, LN-511, LN-111 and LN-121, and are an intact protein or protein fragment. Also included are RPE cells and materials and compositions utilizing such RPE cells for various treatments.

## Claims

### Claim 1

A method for obtaining Retinal Pigment Epithelium (RPE) cells, comprising:
a. providing a culture of human pluripotent stem cells adherent on a first substrate comprising a first laminin;
b. exposing the adherent stem cells to a differentiation medium for a first time period of about 15 days to about 50 days to obtain a first population of adherent cells comprising RPE cells and/or progenitors thereof;
c. at the end of the first time period, dissociating the first population from the first substrate;
d. replating the dissociated first population of cells on a second substrate comprising a second laminin; and
e. culturing the replated first population of cells on the second substrate for second time period to obtain an expanded and matured second population of cells comprising the RPE cells;
wherein the first and second laminins are independently selected from LN-521, LN-511, LN-111 and LN-121, and are an intact protein or protein fragment; and
further comprising quantitating the fraction of cells expressing the marker CD56; and
wherein the dissociation step (c) is initiated when at least 30% of the cells are positive for the marker, or wherein the culturing step (e) is continued until at least 80% of the cells are positive for the marker.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the first and second laminin are coated at an amount of about 5 μg/cm2 to about 20 μg/cm2; or
wherein the first and/or second substrate is/are xeno-free; or
wherein the first and/or second substrate contain only a single laminin.

### Claim 3 (depends on 1)

The method according to claim 1,
wherein the first laminin is LN-111 and the second laminin is LN-521; or
wherein the first and second laminins are both LN-521.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the stem cells are cultured in a stem cell culture medium comprising basic fibroblast growth factor (bFGF) or transforming growth factor beta (TGFbeta), and a Rho-kinase inhibitor is included in the stem cell culture medium for a time period of about 12 hours to about 48 hours prior to the initiation of the exposure to the differentiation medium.

### Claim 10 (depends on 1)

The method according to claim 1, wherein Activin A is included in the differentiation medium.

### Claim 11 (depends on 10)

The method according to claim 10, wherein Activin A is included in the differentiation medium at a concentration of about 50 ng/ml to about 200 ng/ml.

### Claim 12 (depends on 10)

The method according to claim 10, wherein Activin A is included in the differentiation medium no earlier than a time point at about 4 days to about 8 days from the exposure, and ending at the time of the dissociation step.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the first time period is about 15 days to about 40 days.

### Claim 14 (depends on 1)

The method according to claim 1, further comprising quantitating the number or fraction of cells expressing a marker selected from CD140b, CD104, CD164, CD220, or EGFR, wherein the dissociation step (c) is initiated when at least 30% of the cells are positive for the marker, or wherein the culturing step (e) is continued until at least 80% of the cells are positive for the marker.

### Claim 15 (depends on 1)

The method according to claim 1, further comprising quantitating the number or fraction of cells expressing a marker selected from GD2, CD184, CD10, CD30, CD49a, CD49b, CD50, CD171, TRA-1-60, or CD326, wherein the dissociation step (c) is initiated when at least 30% of the cells are negative for the marker, or wherein the culturing step (e) is continued until at least 80% of the cells are negative for the marker.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the dissociated first population of cells are replated without any selection.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the dissociated first population of cells is enriched prior to replating by the steps of:
F1. labelling a cell surface marker on the dissociated first population of cells,
F2. separating the cells that are positive for said cell surface marker from cells that are negative for said cell surface marker to obtain an enriched first population of cells that is more enriched in RPE cells and/or progenitors thereof than the dissociated first population cells; and
F3. using the enriched first population of cells in the replating step.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the cell surface marker is selected from CD140b, CD56, CD104, CD164, CD220, CD165 and EGFR, wherein cells positive for said cell surface marker are selected for the enriched first population of cells.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the cell surface marker is selected from GD2, CD184, CD10, CD30, CD49a, CD49b, CD50, CD171, TRA-1-60, and CD326, wherein cells negative for said cell surface marker are selected for the enriched first population.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the dissociation from the first substrate involves forming a suspension of single cells of the first population of cells; or
wherein the dissociated cells are replated on a second substrate at a cell density from about 1.4×104 cells/cm2 to about 1.4×106 cells/cm2; or
wherein the RPE cells are obtained after a total of 6-12 weeks.
